Transform Modern Medicine Development:
The 21st Century Biology-based Medicine
Use Synthetic Thinking to Intercept Clinical Data: Seeing the Elephant.
Conduct Strategic Review to Build Asset MoA-Disease Maps.
Proven Track Record of Success.
Intangible Assets and Know-How.
If we do know the science around the target or drug, and have a deep understanding of the disease biology, along with expertise of dosing & pharmacology, we can achieve >90% success.
The problem is that most people don’t know what they don’t know, thus fail to see the forest for the trees.
Unique Approach to
1. Solve the Most Difficult Problem in the Development of Modern Medicine: 90% Failure.
2. Find the Right Drug for the Right Patient at the Right Time with the Right Dose!
Tactic: MoA-Disease Match Precision.
1. Retina & Glaucoma Specialty Care and Cornea & Ocular Surface Diseases.
2. Stem Cell & Gene Therapy, Drug and Combination Product Development.
Dr. Tina Guanting Qiu (MD, PhD) is a highly accomplished Biopharma physician executive with 25-year U.S. and international experience in global Pharma, biotech, device and strategic consulting firm. She has acquired top tier know-how skills of product development with proven track records of solving critical problem, turning around situation and maximizing development outcomes that are translated into shareholder value, capital saving and revenue profit. Leadership roles in scientific medical development, business and regulatory strategies, entrepreneurial startups, and external KOLs and shareholder relations.
Dr. Qiu has held position with increased importance at GSK, Inotek Pharma and Sucampo Pharma, and advised senior executives at R&D Clinical Regulatory Commercial Business and Investment. She obtained her Medical Degree with Distinguished Honor at Nanchang University, and Doctorate of Ophthalmology at National Sun Yat-sen University in collaboration with University of Pennsylvania, followed by postdoctoral trainings at Boston University and University Southern California. She lectured widely across the globe and has been featured in “Scientific America” and National Eye Research Center, UK. She is a lawful US Citizen since 2011.
Industry Background: Astellas Pharma, Sanofi Aventis, GlaxoSmothKline, Inotek Pharma, Sucampo Pharma, LambdaVision, Ocular Therapeutics, Spiral Therapeutics, Gerson Lehmarn Group.
Cornea & Ocular Surface Disorder :
OTI Introductory Video:
OTI Scientific Gallery:
IND and Phase 1-4 Clinical Protocol & Medical Strategy.
Conduct Strategic Review to Build Asset MoA-Disease "Map" Franchise Indication & New Product Planning
Product Development Path-Finding to IND Enabling Stage
(up to 80% saving)
IND Package Review & "Must-Have"
KOLs Development & SAB Relations
Strategic Scientific Communication
Product Launch Taskforce
Product Medical Strategy
Medical Education & Trainings